Tonix sublingual therapy for fibromyalgia set for Phase III; Arch Therapeutics aims to stop bleeding during surgery;

> Tonix Pharmaceuticals said it will begin the Phase III clinical trial of its sublingual reformulation of cyclobenzaprine to treat fibromyalgia in the second quarter of this year because the has FDA accepted its proposed primary outcome measure of pain reduction. The company missed a different outcome measure of pain reduction in a Phase IIb study, but appears to have convinced FDA to let it use a different proxy for pain reduction this time around. Release

> Arch Therapeutics said preclinical tests of its AC5 Surgical Hemostatic Device were positive, as it aims develop a medical device to stop bleeding during surgery based on its self-assembling peptide technology platform. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.